Primary percutaneous coronary intervention for ST elevation myocardial infarction in nonagenarians by Petroni T et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International 
License 
 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Petroni T, Zaman A, Georges JL, Hammoudi N, Berman E, Segev A, Juliard JM, 
Barthelemy O, Silvain J, Choussat R, Le Feuvre C, Helft G.  
Primary percutaneous coronary intervention for ST elevation myocardial 
infarction in nonagenarians.  
Heart 2016, 102(20), 1648-1654. 
 
Copyright: 
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non 
Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work 
non-commercially, and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ 
DOI link to article: 
https://doi.org/10.1136/heartjnl-2015-308905  
Date deposited:   
08/03/2018 
  
ORIGINAL ARTICLE
Primary percutaneous coronary intervention for ST
elevation myocardial infarction in nonagenarians
Thibaut Petroni,1 Azfar Zaman,2 Jean-Louis Georges,3 Nadjib Hammoudi,1
Emmanuel Berman,1 Amit Segev,4 Jean-Michel Juliard,5 Olivier Barthelemy,1
Johanne Silvain,1 Rémi Choussat,1 Claude Le Feuvre,1 Gérard Helft1
1Cardiology Institute, Pitié-
Salpêtrière Hospital, UPMC,
APHP, Paris, France
2Freeman Hospital and
Institute of Cellular Medicine,
Newcastle University,
Newcastle Upon Tyne, UK
3Centre Hospitalier de
Versailles, André Mignot
Hospital, Le Chesnay, France
4Heart Institute, Chaim Sheba
Medical Center, Tel-Hashomer,
Israël
5Bichat Hospital, APHP, Paris,
France
Correspondence to
Professor Gérard Helft,
Cardiology Institute, Pitié-
Salpêtrière Hospital, 47-83,
boulevard de l’hôpital, Paris
75013, France;
gerard.helft@psl.aphp.fr
Received 26 October 2015
Revised 28 April 2016
Accepted 29 April 2016
Published Online First
13 July 2016
To cite: Petroni T,
Zaman A, Georges J-L, et al.
Heart 2016;102:
1648–1654.
ABSTRACT
Objective To assess outcomes following primary
percutaneous coronary intervention (PCI) for ST-segment
elevation acute myocardial infarction (STEMI) in
nonagenarian patients.
Methods We conducted a multicentre retrospective
study between 2006 and 2013 in five international high-
volume centres and included consecutive all-comer
nonagenarians treated with primary PCI for STEMI. There
were no exclusion criteria. We enrolled 145 patients and
collected demographic, clinical and procedural data.
Severe clinical events and mortality at 6 months and
1 year were assessed.
Results Cardiogenic shock was present at admission in
21%. Median (IQR) delay between symptom onset and
balloon was 3.7 (2.4–5.6) hours and 60% of procedures
were performed through the transradial approach.
Successful revascularisation of the culprit vessel was
obtained in 86% of the cases (thrombolysis in
myocardial infarction flow of 2 or 3). Major or clinically
relevant bleeding was observed in 4% of patients.
Median left ventricular ejection fraction post PCI was
41.5% (32.0–50.0). The in-hospital mortality was 24%,
with 6 months and 1-year survival rates of 61% and
53%, respectively.
Conclusions In our study, primary PCI in
nonagenarians with STEMI was achieved and feasible
through a transradial approach. It is associated with a
high rate of reperfusion of the infarct-related artery and
53% survival at 1 year. These results suggest that
primary PCI may be offered in selected nonagenarians
with acute myocardial infarction.
INTRODUCTION
Medical and technical progress has led to increased
life expectancy, resulting in a significant proportion
of very old patients with specific health problems.
In this growing population, cardiovascular disease
is frequent and ischaemic heart disease remains one
of the leading causes of morbidity and mortality.1 2
However, most clinical trials exclude patients aged
>75–80 years as prolonged follow-up may be com-
promised by limited life expectancy. It also appears
that side effects of new therapies are mostly
observed in patients aged >75 years.3 Other factors
such as atypical symptoms, delayed presentation
and associated comorbidities further add to
advanced age as being one of the most powerful
predictors of adverse outcome in acute coronary
syndromes.4 As a result, elderly patients >75 years
old are under-represented in clinical trials.5–8
Additionally, prior studies have reported an
increased rate of vascular complications, bleeding
and cardiac mortality associated with percutaneous
coronary intervention (PCI) in the elderly.9–11 As a
consequence, it is difficult to assess the risk/benefit
balance for care protocols and pharmacological
interventions in these patients.12 To date, no clin-
ical randomised trial is available for the manage-
ment of ST-segment elevation myocardial infarction
(STEMI) in elderly patients. Non-revascularised
patients admitted with STEMI are known to carry
poor outcomes.13 14 Even though primary PCI has
been established as the standard of care, a conserva-
tive strategy is often adopted when facing this situ-
ation in nonagenarians.15 16 The first case report of
primary PCI in a nonagenarian was published in
2002.17 Few studies based on cohorts have sug-
gested feasibility for invasive management of
STEMI in nonagenarians.18–21 Our team has
recently published the outcome of the largest series
of nonagenarians presenting with STEMI, but data
are limited to in-hospital follow-up only.22
Through this paper, we present data of the largest
series of consecutive patients aged 90 years or
older admitted with STEMI and treated by primary
PCI in contemporary practice.
METHODS
Study population
We retrospectively enrolled 145 consecutive
patients aged ≥90 years hospitalised for STEMI
and treated with primary PCI in five international
high-volume centres between 2006 and 2013.
These centres were Freeman hospital (Newcastle
Upon Tine, UK), Pitié-Salpêtrière teaching hospital
(Paris, France), Chaim-Sheba Medical Center
(Tel-Hashomer, Israel), André Mignot hospital
(Versailles, France) and Bichat teaching hospital
(Paris, France) and respectively provided 46, 43,
28, 20 and 8 patients. Their respective numbers of
primary PCI in 2013 were 250, 350, 290, 112 and
200. All patients had follow-up during in-hospital
stay, with completed baseline characteristics,
pharmacological management, angiographic find-
ings and procedure results. A 12-month follow-up
was obtained during patients’ visit to outpatient
clinics or by telephone interview. The inclusion cri-
teria for primary PCI were clinical symptoms (such
as general weakness, thoracic symptoms, eg, persist-
ing chest pain over 30 min or dyspnoea, digestive
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symptoms such as nausea or vomiting, neurological alteration
including acute confusional state) combined with electrocardio-
graphic ST-segment elevation over 1 mV in at least two contigu-
ous leads and admission within 12 hours of symptoms onset or
24 hours for patients with evidence of continuing ischaemia.
There were no exclusion criteria.
Cardiac catheterisation
The interventional procedure was performed by senior interven-
tional cardiologists using 6 Fr guiding catheters in all cases once
verbal consent for treatment had been obtained from the patient
or relatives. The vast majority of patients received a loading
dose of two antiplatelet therapies and heparin before PCI. The
choice of antithrombotic therapy, the use of thrombus aspiration
catheter and the type of stent were left to the discretion of the
attending interventionist.
Outcomes evaluation
All patients were observed in a coronary care unit for at least
24 hours before discharge or transfer. We recorded the inci-
dence of severe clinical events such as death, recurrent myocar-
dial infarction, target vessel revascularisation, stroke,
procedure-related complications, acute renal failure and major
or clinically relevant bleeding during hospitalisation. Survival
data at 6 months and 1 year were collected. A successful proced-
ure was defined as achievement of thrombolysis in myocardial
infarction (TIMI) grade 2 or 3 flow, <50% residual stenosis and
absence of any major clinical adverse event within 24 hours.
A failed procedure was defined as resulting in TIMI grade 0–1
flow regardless of residual stenosis with the absence of any
major clinical adverse event within 24 hours. This could result
from no reflow phenomenon or coronary dissection. A compli-
cated procedure was defined as resulting in death, recurrent
myocardial infarction (ie, at least doubling creatine kinase from
the initial value with >10% of creatine kinase-MB fraction
(CK-MB)) within 24 hours. Major and minor bleeding events
were defined using the criteria of the TIMI trial group and
acute renal failure was defined as an absolute increase in serum
creatinine of at least 0.3 mg/dL (26.4 mmol/L) or a percentage
increase in serum creatinine of at least 50% according to the
Risk, Injury, Failure, Loss and End-Stage Kidney Disease
criteria.
Statistical analysis
Continuous variables are expressed as median and IQR, and dis-
crete variables as absolute values and percentages. The log-rank
test was used to compute the significance of time-to-event data,
and survival rates were estimated using the Kaplan-Meier
method. The Kaplan-Meier curve was plotted through day 730
(2 years). An additional Cox proportional hazard regression ana-
lysis was performed to describe the effects of gender and age on
survival, with and without adjustment on centre. Analyses were
performed using SPSS software V.23 (IBM, Armonk, New York,
USA).
RESULTS
Patient demographics
Median (IQR) age was 92 (91–94) years (extreme 90–102) with
the majority female (62%) and associated comorbidities were
low. Baseline characteristics of the study population are reported
in table 1, and biological parameters are summarised in table 2.
In this cohort, no patient was admitted for asymptomatic
acute myocardial infarction. The clinical presentation of these
patients was severe with 43% in Killip class II–IV including
nearly a third presenting with cardiogenic shock or severe
pulmonary oedema.
Antithrombotic management
Antithrombotic management of the patients is recorded in
table 3. All patients received an intravenous loading dose of
aspirin between 250 and 500 mg before the procedure. P2Y12
inhibitors were administered in 97% of the cases and consisted
majorly in clopidogrel loading (300–600 mg). Glycoprotein IIb/
IIIa inhibitors, predominantly abciximab, were administered
during the cardiac catheterisation in 36% of the patients.
Heparin, predominantly unfractionated heparin, was used in
Table 2 Biological parameters
Biological data
Cardiac troponin (cTnI) peak (ng/mL) 45.0 (10.9–94.0)
Creatine kinase peak (UI/L) 932.0 (111.5–2468.0)
Haemoglobin at admission (g/dL) 11.9 (11.0–12.8)
Nitrogen urea at admission (mmol/L) 11.9 (6.7–15.2)
Serum creatinine at admission (mmol/L) 111.0 (89.0–139.7)
Creatinine clearance (mL/min)—MDRD 49.0 (36.8–61.0)
Cholesterol (g/L) 1.66 (1.43–1.94)
LDL-C (g/L) 0.92 (0.72–1.09)
HDL-C (g/L) 0.52 (0.42–0.65)
Triglyceride (mmol/L) 0.82 (0.66–1.05)
Fibrinogen (g/L) 4.1 (3.5–5.0)
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
MDRD, Modification of the Diet in Renal Disease.
Table 1 Baseline demographics and clinical data
Baseline characteristics
Age (years) 92.0 (91.0–94.0)
Sex ratio (% men) 38
Body mass index (kg/m2) 23.4 (21.0–25.5)
Hypertension (%) 53
Hyperlipidaemia (%) 25
Diabetes mellitus (%) 14
Active smoker (%) 8
History of coronary heart disease (%)
Previous MI 24
Previous PCI 4
Previous CABG 5
Clinical presentation (%)
Chest pain 86
Dyspnoea 21
Killip class at admission (%)
I 57
II 12
III 10
IV 21
LVEF at admission (%) 41.5 (32.0–50.0)
Electrocardiographic presentation (%)
Anterior STEMI location 39
LBBB 4
STEMI with ST elevation in avR 3
CABG, coronary artery bypass graft; LBBB, left bundle branch block; LVEF, left
ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary
intervention; STEMI, ST-segment elevation MI.
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90% of cases. Unfractionated heparin was administered at
100 UI/kg before the beginning of the procedure with additional
doses at the discretion of the physician. When chosen,
low-molecular-weight heparin was administered at an intraven-
ous loading dose of 0.5 mg/kg, then additional doses if neces-
sary depending on procedure duration.
Angiographic and procedural characteristics
The median time from symptom onset to PCI was 3.7 (2.4–
5.6) hours. Primary PCI was performed within 6 hours after
symptoms onset in 78% of cases. Angiographic findings and
interventional procedure are detailed in table 4. The transradial
approach was feasible in the majority (60%) but varied between
centres from 40% to 84%. Successful coronary revascularisation
was obtained in 94% of the patients with an overall successful
procedure rate of 86%. Failed PCI occurred in 11% of the
patients, mostly resulting from distal embolisation or coronary
dissection or inability to pass the wire through the thrombus.
Complicated PCI was observed in 3% of the patients, mostly
resulting from cardiac arrest during primary PCI, either due to
refractory cardiogenic shock, refractory ventricular fibrillation
or asystole. This was due to left main coronary rupture during
angioplasty in one case and to no reflow in another one. During
procedure, 26% of the patients received inotropic support,
mainly with dobutamine, but none had intra-aortic counterpul-
sation support.
Clinical outcomes
The median hospital stay was 4.0 (2.0–6.5) days (extreme
1–28 days) with coronary care unit stay not prolonged over
3 days. Longer hospital stay was mostly due to social issues.
Very short hospital stays (<2 days) resulted in transfers back to
the originating cardiology units from where patients were first
referred. In-hospital outcomes are shown in table 5.
Of significance, despite intensive antiplatelet and anticoagu-
lant therapy, major or clinically relevant bleeding events were
recorded in only six patients (4%) during in-hospital follow-up.
Ventricular arrhythmias occurred in 17% of patients, all within
24 hours of procedure. Acute renal failure complicated the
interventional procedure in 10% with favourable resolution in
half.
The overall in-hospital mortality was 24%. Patients with
Killip class I, II, III and IV at admission experimented in-hospital
mortality of 12.2%, 11.8%, 26.7% and 47.8%, respectively.
Pharmacological management at discharge and follow-up
At discharge, all but one patient were taking aspirin with 94%
on dual antiplatelet therapy. No platelet function assessment or
genetic tests were performed in these patients. The pharmaco-
logical management of patients is presented in table 6.
Complete follow-up was obtained at 6 and 12 months, but
26% of the patients were lost to follow-up at 24 months. In
total, 6-month, 1-year and 2-year overall survival rates were
61% (95% CI 53% to 69%), 53% (45% to 61%) and 43%
(34% to 52%), respectively (figure 1). Almost all (92%) cardio-
vascular deaths occurred before day 30 in contrast to non-
cardiovascular deaths. Two-year survival was significantly lower
in females versus males (p<0.05) and in patients with anterior
STEMI (p<0.01) (figure 2). Lower survival in females remained
after adjustment on age and centre (Hazard Ratio vs males 1.72,
95% CI 1.08 to 2.77; p<0.03).
Table 3 Antithrombotic therapy pre or per PCI
Antithrombotic treatment
Aspirin (%) 99
Clopidogrel (%) 94
Prasugrel (%) 3
Ticagrelor (%) 0
Glycoprotein IIbIIIa inhibitors (%) 36
Heparin (%) 90
LMWH (%) 23
Bivalirudin (%) 1
LMWH, low-molecular weight heparin; PCI, percutaneous coronary intervention.
Table 4 Angiographic characteristics and procedural information
Procedural findings
Time from symptoms to PCI (hours) 3.7 (2.4–5.6)
Catheterisation access (%)
Radial 60
Single-vessel coronary disease (%) 53
Single-vessel coronary PCI (%) 74
Infarct-related coronary artery (%)
Left main 4
Left anterior descending 41
Circumflex 14
Right 45
CABG 3
Thrombus aspiration (%) 14
TIMI flow grade after procedure (%)
0 12
1 1
2 6
3 81
Coronary stenting (%)
BMS 75
DES 9
POBA 10
Procedure success (%)
Successful PCI 86
Failed PCI 11
Complicated PCI 3
Use of protection device (%) 2
IABP (%) 0
Use of inotropes during procedure (%) 26
BMS, bare metal stent; CABG, coronary artery bypass graft; DES, drug-eluting stent;
IABP, intra-aortic balloon pump; PCI, percutaneous coronary intervention; POBA, plain
old balloon angioplasty; TIMI, thrombolysis in myocardial infarction.
Table 5 In-hospital outcomes
Death (%) 24
Recurrent MI (%) 1
Target vessel revascularisation (%) 4
Ventricular arrhythmias (%) 17
Major or clinically relevant bleeding (%) 4
Acute renal failure (%) 10
Stroke (%) 1
MI, myocardial infarction.
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DISCUSSION
Previous studies have highlighted the increased rate of proced-
ural failure and complications when performing PCI in very old
patients,9 23 and data consistently report age to be a strong pre-
dictor of mortality. This is particularly high in nonagenarians at
30 days and 1 year and increases with the extent of coronary
artery disease and associated conditions.1–4 Nevertheless, the
results of this study of contemporary practice show that selected
nonagenarians presenting with STEMI can be successfully and
safely treated by primary PCI.
This study provides interesting data on the characteristics of
highly selected cohort. The clinical presentation of an acute
myocardial infarction in this specific population may be very dif-
ferent from that seen in younger patients, ranging from com-
pletely asymptomatic to general weakness or various thoracic,
digestive or neurological symptoms. In our series, all patients
presented with thoracic symptoms (acute chest pain and/or
shortness of breath), which may be due to a selection bias. For
all that, physicians should be aware of atypical and non-specific
symptoms, especially abdominal symptoms such as nausea,
vomiting, abdominal pain and diarrhoea, weakness and altered
mental status. As expected in this population, the majority in
our cohort had multivessel coronary disease and mild-to-severe
altered left ventricular dysfunction. The prevalence of presenta-
tion in Killip class III and IV was high, >30% in our series.
This figure may be higher as a number of this population may
have not been identified as Killip class IV at admission due to
the absence of hypotension and the paucity of clinical symptoms
as hypoperfusion may be difficult to diagnose in the elderly.
The first point to discuss is the unexpectedly low rate of com-
plications in our series. Although PCI was found to be asso-
ciated with a higher rate of complications and mortality in
patients aged >75 years in other studies,24–26 we noticed
acceptable rates of in-hospital major complications, especially
regarding stroke or major bleeding complications with low inci-
dence of acute renal failure. Despite intensive antiplatelet
Table 6 Treatment at hospital discharge
Aspirin (%) 99
Clopidogrel (%) 94
Prasugrel (%) 3
PPI (%) 79
Beta-blockers (%) 66
Statins (%) 81
CEI or ARA (%) 62
Aldosterone inhibitors (%) 0
Vitamin K antagonist (%) 0
Amiodarone (%) 21
ARA, angiotensin receptors antagonists; CEI, converting enzyme inhibitors; PPI,
proton pump inhibitors.
Figure 1 Kaplan-Meier curves of
survival after primary percutaneous
coronary intervention for overall
mortality (A) and 1-year cardiovascular
(B) and non-cardiovascular (C)
mortality.
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therapy including use of glycoprotein IIb/IIIa inhibitors and
most often 600 mg clopidogrel initial loading dose, no fatal or
severely disabling bleeding such as intracranial haemorrhage was
reported in-hospital. The high rate of procedures conducted
through the transradial approach may explain the low rate of
access site bleeding complications. Of the six patients who had
clinically relevant bleeding, only one received glycoprotein
IIbIIIa inhibitors and two underwent femoral access procedures.
The very old patients are also at increased risk of
contrast-induced acute renal injury and acute renal failure.
Indeed, primary PCI with iodinated contrast agents increases
the risk of contrast-induced nephropathy exacerbated by altered
renal clearance at admission and the frequent Killip III/IV pres-
entation with associated organ hypoperfusion. However, even
though the creatinine clearance may have dropped in some
patients during hospital stay, this alteration of renal function
was observed to be transient except in those with fatal outcome
and it is important to note that no death resulted from a renal-
related cause.
The second point of discussion is the antithrombotic strategy.
A significant administration of low-molecular-weight heparin
was observed in some recruiting centres and is consistent with
its benefit over unfractionated heparin previously reported in
other studies.27 However, its role in the oldest old can be
questioned as mean creatinine clearance at admission
approaches 30 mL/min. Furthermore, the choice of the antipla-
telet therapy should be carefully made. Although no early bleed-
ing occurred in our series, to date, data remain consistent for
clopidogrel prescription over any other thienopyridine, which
could increase the long-term bleeding risk. It must be remem-
bered that in some cases oral administration of clopidogrel
could be compromised or delayed as a high proportion of the
patients may be unable to swallow anything in the context of
pulmonary oedema or cardiogenic shock and altered conscious
state. Nevertheless, bleeding complications may have occurred
after hospital discharge. Prasugrel was rarely administered due
to the time period of inclusion and advanced age population.
However, new P2Y12 inhibitors appear as an interesting alterna-
tive to clopidogrel in selected patients.28 Further data may
shortly be available in this field (SENIOR study, NCT
02099617).
The third point of discussion is the delay of primary PCI. We
found a mean delay from symptoms to primary PCI at 5.8
±7.6 hours, which is a consequence of multiple factors includ-
ing difficulties in diagnosis and sometimes refusal from other
healthcare organisations to perform interventional procedures in
elderly patients based on outdated data and their own percep-
tion of the risk-to-benefit ratio. The recognition of the benefits
of primary PCI in the oldest old should lead to carers and
public health measures, recognising that the earlier the diagnosis
is made and the patient referred to the catheterisation labora-
tory, the better will be the outcome from primary PCI.
Considering this last argument, additional data provided by our
study may help to change current perceptions and potentially
influence guidelines on the management of STEMI.29
The fourth point of discussion is the global short-term and
long-term outcomes. Survival rate at hospital discharge is con-
sistent with previous studies, thus making the case for primary
PCI in selected nonagenarian patients presenting with STEMI.
Helft et al recently reported a 24.9% mortality rate in a cohort
of 418 nonagenarians with STEMI and in-hospital follow-up
only, very close to the 24% mortality rate that we noticed. In
our series, as in both registries authored by Danzi et al18 and
Rigattieri et al,21 6-month survival rates looked similar (61%,
67% and 68%, respectively). In patients who were discharged
alive, 1-year cardiovascular mortality was very low (only one
cardiovascular death from day 30 through 1-year of follow-up).
Survival rates were higher than those reported in non-
reperfused elderly STEMI patients (in-hospital and 1-year mor-
tality rates of 53% and 69%, respectively, in a cohort of 139
octogenarians).14 Overall survival was in the range of that in
general population aged >90 years in France (age-specific
annual death rates between ages 90 and 94 years of 15% in
females and 21% in males).30
However, we recognised some limitations to our study. The
main limitation of this study is that there is no comparison
group, such as nonagenarians with STEMI who were not
managed with primary PCI. This may be problematic because
the study cohort appears to be highly selected with remarkably
low comorbidity profile. As our study is retrospective and non-
randomised, it is not possible to draw definite conclusions over
the absolute benefit of primary PCI. The generalisability of the
study findings to other very old patients treated at other institu-
tions with perhaps less experienced interventionalists is also
uncertain. Another important limitation is that we cannot
provide data on functional outcomes following the procedure.
The proportion of patients who were able to return to their pre-
vious level of functioning remains unknown. The proportion of
Figure 2 Kaplan-Meier curves showing survival in males versus
females (A) and in patients with anterior versus non-anterior
ST-segment elevation myocardial infarction (STEMI) (B).
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patients who previously lived in the community and subse-
quently required institutionalisation is lacking as well. An
unknown proportion of patients may have had new activities of
daily living or instrumental activities of daily living
dependencies.
In summary, the developed world is ageing and clinical trials
typically exclude elderly patients over the age of 75 years.
Following myocardial infarction, the outcomes in the oldest old
patients are poor and there are limited data in patients
>90 years of age. Our data support the use of primary PCI to
benefit this specific category of population. Finally, these find-
ings show that in keeping with previous series primary PCI is
technically feasible in very old patients, with a lower rate of
complications than expected, a lower mortality than expected
and successful angiographic and clinical results at short-term
and longer follow-up. The transradial approach may be rou-
tinely chosen by experienced operators to reduce adverse
events, particularly puncture site-related bleeding complications.
The data presented from several centres in different countries
are the largest series to date with the longest follow-up. Our
study provides some evidence that in contemporary practice
mechanical reperfusion of STEMI in nonagenarians may
improve the in-hospital and long-term outcomes.
CONCLUSION
This study suggests that primary PCI can be safely and success-
fully performed in nonagenarians presenting with STEMI
through a transradial approach. Similar to younger patients in
previous large randomised trials, this invasive strategy is asso-
ciated with a high rate of achieved reperfusion of the
infarct-related artery and low incidence of procedure-related
complications in this specific population. Use of contemporary
strategies in our series was associated with a lower mortality rate
than expected considering the severe clinical presentation, and
this may be further improved with earlier patient referral. These
results should encourage primary PCI to be offered to selected
nonagenarians with acute myocardial infarction. Further clinical
studies involving a larger cohort of elderly patients and newer
antithrombotic approaches may help to better define the bene-
fits and risks ratio of primary PCI in nonagenarians with STEMI
especially in terms of quality of life.
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